- 12.5mg Chlorthalidone – Box x30 tablets.
- 25mg Chlorthalidone – Box x30 tablets.
Treatment of arterial hypertension and isolated systolic hypertension.
Adults 12.5 to 25 mg/day.
Hypersensitivity to any component of the formula. It should not be administered to patients with anuria, renal or hepatic insufficiency, hypokalaemia, refractory hypercalcaemia, hyponatremia, hypomagnesaemia, hypophosphatemia, hyperuricaemia or lupus erythematosus, a history of gout or uric acid stones.
Interaction with other medications
Potentiates hyperglycemia induced by diazoxide, also decreasing the hypoglycemic activity of chlorpropamide. This drug can decrease the response to norepinephrine, the joint use with lithium is not recommended, because toxicity can occur due to the reduced renal clearance and the nephrotoxic effects of lithium. HIDROTEN® can reduce the effects of anticoagulants, uricosurics, sulfonylureas and insulin. HIDROTEN® increases the effect of anesthetics, diazoxide, glycosides, other diuretics and vitamin D. The joint administration of NSAIDs decreases the effectiveness of HIDROTEN®. Corticosteroids, amphotericin B, corticotrophin, hypoglycemic agents, amiodarone, angiotensin-converting enzyme inhibitors, antihypertensives, digitalis, quinidine, and cyclosporine.
In diabetic patients controlled with hypoglycemic agents or insulin, chlorthalidone should be administered with extreme caution, and if necessary, adjust the doses of hypoglycemic agents and/or insulin. Chlorthalidone can potentiate the effects of digitalis poisoning, as well as hypotension due to other antihypertensives.